IONIS PHARMACEUTICALS INC
IONSNasdaq
$54.39
↓ -0.5%Jul 17 close · end-of-day
Price
1Y↑ +27.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$9.0B
Enterprise Value
$7.0B
P/E
—
P/S
8.5
P/B
18.2
EV/EBITDA
—
PEG
—
FCF Yield
-10.8%
Dividend Yield
—
Revenue (TTM)
$1.1B
Net Income (TTM)
-$327.0M
Free Cash Flow (TTM)
-$971.3M
Gross Margin
—
Operating Margin
-33.3%
Net Margin
-30.9%
ROE
-66.5%
ROIC
—
Debt / Equity
—
Net Cash
$1.9B
Return 1Y
+29.0%
Company profile
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy.
- CEO
- Brett P. Monia
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 800
- Headquarters
- California
- Website
- ionispharma.com
Management & directors
- Bennett C FrankEVP, Chief Scientific Officer
- Kordasiewicz Holly B.EVP, Chief Development Officer
- Baroldi JosephEVP, Chief Business Officer
- Monia Brett PChief Executive Officer
- O'Neil Patrick R.EVP CLO & General Counsel
- Schneider EugeneEVP, Chf Clinical Develop Ofcr
- Swayze EricEVP Research
- Birchler BrianEVP, Corp and Development Ops
- Jenne KyleEVP, Chf GL Pdt Str Ofcr
- Devers Shannon L.EVP, Chief Human Resources Ofc
- Hougen Elizabeth LEVP, Finance & CFO
- Geary Richard SEVP, Chief Development Officer
Roles derived from SEC Form 4 filings.
Earnings
IONS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$246.1M↑ +87.0%
Diluted EPS-$0.56↓ -39.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $729.3M | $810.5M | $587.4M | $787.6M | $705.1M | $943.7M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$172.1M | -$30.2M | -$410.2M | -$353.7M | -$475.1M | -$381.7M |
| Net income | -$444.3M | -$28.6M | -$269.7M | -$366.3M | -$453.9M | -$381.4M |
| Diluted EPS | -$3.18 | -$0.20 | -$1.90 | -$2.56 | -$3.04 | -$2.38 |
| Operating cash flow | $35.9M | $30.8M | -$274.4M | -$307.5M | -$500.9M | -$268.6M |
| Free cash flow | $772,000.00 | $18.8M | -$290.1M | -$331.3M | -$546.2M | -$320.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -23.6% | -3.7% | -69.8% | -44.9% | -67.4% | -40.4% |
| Net margin | -60.9% | -3.5% | -45.9% | -46.5% | -64.4% | -40.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q2 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $225.3M | $133.8M | $226.6M | $131.6M | $452.0M | $156.7M | $203.3M | $246.1M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$66.1M | -$148.7M | -$110.8M | -$146.9M | $139.8M | -$160.2M | -$214.5M | -$117.4M |
| Net income | -$66.3M | -$140.5M | -$104.3M | -$146.9M | $123.6M | -$128.6M | -$229.4M | -$92.5M |
| Diluted EPS | -$0.45 | -$0.95 | -$0.66 | -$0.93 | $0.70 | -$0.80 | -$1.41 | -$0.56 |
| Operating cash flow | -$119.9M | -$115.0M | -$116.1M | -$150.8M | $151.3M | -$131.4M | -$137.7M | -$792.8M |
| Free cash flow | -$126.1M | -$124.0M | -$141.6M | -$163.4M | $139.0M | -$136.7M | -$159.0M | -$814.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -29.3% | -111.1% | -48.9% | -111.6% | 30.9% | -102.2% | -105.5% | -47.7% |
| Net margin | -29.4% | -105.0% | -46.1% | -111.6% | 27.3% | -82.1% | -112.8% | -37.6% |
Company news
Jul 14, 2026
- 6d agoBiogen Slumps As Alzheimer's Study Leaves 'More Questions Than Answers'finance.yahoo.com
- 6d agoMorgan Stanley Raises its Price Target on Alnylam (ALNY)finance.yahoo.com
- 6d agoIonis Begins Dosing in Phase I/II Dravet Syndrome Studyfinance.yahoo.com
- 6d agoCan Biogen Score Another Win In Alzheimer's Disease?finance.yahoo.com
- 6d agoIonis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Diseasefinance.yahoo.com
Jul 13, 2026
- 7d agoBiogen Stock Is Upgraded to Buy Ahead of Key Alzheimer’s Drug Study Detailsfinance.yahoo.com
- 7d agoThe Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directionsmarketbeat.com
- 7d agoIonis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndromefinance.yahoo.com
- 7d agoCan Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer’s?finance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | BERTHELSEN SPENCER R | Option exercise | 5,220 | $0.00 | $0.00 | filing |
| 2026-07-15 | HERMAN JOAN E | Option exercise | 5,220 | $0.00 | $0.00 | filing |
| 2026-07-07 | BENNETT C FRANK· EVP, Chief Scientific Officer | Sale | 15,000 | $85.46 | $1.3M | filing |
| 2026-07-07 | Diaz Allene M. | Sale | 10,111 | $85.42 | $863,637.13 | filing |
| 2026-07-07 | Diaz Allene M. | Option exercise | 10,111 | $47.11 | $476,329.21 | filing |
| 2026-07-07 | BENNETT C FRANK· EVP, Chief Scientific Officer | Sale | 5,536 | $83.58 | $462,693.34 | filing |
| 2026-07-07 | Kordasiewicz Holly B.· EVP, Chief Development Officer | Sale | 362 | $84.30 | $30,516.60 | filing |
| 2026-07-07 | BENNETT C FRANK· EVP, Chief Scientific Officer | J | 15,000 | $0.00 | $0.00 | filing |
| 2026-07-01 | KLEIN JOSEPH III | Sale | 11,419 | $79.04 | $902,550.91 | filing |
| 2026-07-01 | KLEIN JOSEPH III | Option exercise | 11,518 | $39.94 | $460,028.92 | filing |
| 2026-07-01 | KLEIN JOSEPH III | Sale | 99 | $79.45 | $7,865.55 | filing |
| 2026-06-26 | Monia Brett P· Chief Executive Officer | Sale | 50,000 | $80.59 | $4.0M | filing |
| 2026-06-26 | Monia Brett P· Chief Executive Officer | Option exercise | 50,000 | $56.78 | $2.8M | filing |
| 2026-06-26 | Schneider Eugene· EVP, Chf Clinical Develop Ofcr | Sale | 26,000 | $81.05 | $2.1M | filing |
| 2026-06-26 | Schneider Eugene· EVP, Chf Clinical Develop Ofcr | Option exercise | 26,000 | $60.89 | $1.6M | filing |
| 2026-06-26 | Baroldi Joseph· EVP, Chief Business Officer | Sale | 5,635 | $80.16 | $451,698.78 | filing |
| 2026-06-26 | O'NEIL PATRICK R.· EVP CLO & General Counsel | Sale | 3,069 | $80.00 | $245,520.00 | filing |
| 2026-06-26 | Baroldi Joseph· EVP, Chief Business Officer | Option exercise | 3,866 | $56.78 | $219,511.48 | filing |
| 2026-06-26 | Baroldi Joseph· EVP, Chief Business Officer | Option exercise | 1,769 | $32.60 | $57,669.40 | filing |
| 2026-06-25 | Monia Brett P· Chief Executive Officer | Sale | 21,072 | $78.49 | $1.7M | filing |
| 2026-06-25 | Swayze Eric· EVP Research | Sale | 10,602 | $79.18 | $839,491.80 | filing |
| 2026-06-25 | Monia Brett P· Chief Executive Officer | Option exercise | 21,072 | $32.60 | $686,947.20 | filing |
| 2026-06-24 | Monia Brett P· Chief Executive Officer | Sale | 14,565 | $78.41 | $1.1M | filing |
| 2026-06-24 | Monia Brett P· Chief Executive Officer | Option exercise | 14,565 | $32.60 | $474,819.00 | filing |
| 2026-06-15 | BERTHELSEN SPENCER R | Sale | 8,000 | $73.49 | $587,920.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.